<div class="infobox infobox-protein"> | Property | Value | |----------|-------| | Protein Name | Nicotinic acetylcholine receptor subunit alpha-1 | | Gene | [CHRNA1](/genes/chrna1) | | UniProt ID | [P30531](https://www.uniprot.org/uniprot/P30531) | | PDB ID | 2QC1, 5KLE | | Molecular Weight | ~55 kDa | | Subcellular Localization | Plasma membrane (ligand-gated ion channel) | | Protein Family | Cys-loop receptor family; Nicotinic acetylcholine receptor | </div>
Overview
Nicotinic [acetylcholine](/entities/acetylcholine) receptor subunit alpha-1 is a protein encoded by the [CHRNA1](/genes/chrna1) gene that in the normal nervous system, chrna1 is primarily expressed at the neuromuscular junction where it mediates neuromuscular signaling:. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
Structure
The CHRNA1 protein encodes the alpha-1 subunit of the nicotinic acetylcholine receptor (nAChR), a ligand-gated ion channel composed of five subunits (2 alpha, 1 beta, 1 delta, 1 gamma/epsilon). The protein contains:
Extracellular N-terminal domain: Contains the acetylcholine binding site
Cys-loop motif: Characteristic of the Cys-loop receptor family
Four transmembrane domains (M1-M4): Form the ion channel pore
Intracellular loop: Between M3 and M4, involved in channel trafficking and regulation
...
CHRNA1 Protein
<div class="infobox infobox-protein"> | Property | Value | |----------|-------| | Protein Name | Nicotinic acetylcholine receptor subunit alpha-1 | | Gene | [CHRNA1](/genes/chrna1) | | UniProt ID | [P30531](https://www.uniprot.org/uniprot/P30531) | | PDB ID | 2QC1, 5KLE | | Molecular Weight | ~55 kDa | | Subcellular Localization | Plasma membrane (ligand-gated ion channel) | | Protein Family | Cys-loop receptor family; Nicotinic acetylcholine receptor | </div>
Overview
Nicotinic [acetylcholine](/entities/acetylcholine) receptor subunit alpha-1 is a protein encoded by the [CHRNA1](/genes/chrna1) gene that in the normal nervous system, chrna1 is primarily expressed at the neuromuscular junction where it mediates neuromuscular signaling:. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
Structure
The CHRNA1 protein encodes the alpha-1 subunit of the nicotinic acetylcholine receptor (nAChR), a ligand-gated ion channel composed of five subunits (2 alpha, 1 beta, 1 delta, 1 gamma/epsilon). The protein contains:
Extracellular N-terminal domain: Contains the acetylcholine binding site
Cys-loop motif: Characteristic of the Cys-loop receptor family
Four transmembrane domains (M1-M4): Form the ion channel pore
Intracellular loop: Between M3 and M4, involved in channel trafficking and regulation
The alpha-1 subunit can form receptors with beta-1, delta, and gamma (fetal) or epsilon (adult) subunits at the neuromuscular junction.
Normal Function
In the normal nervous system, CHRNA1 is primarily expressed at the neuromuscular junction where it mediates neuromuscular signaling:
Neuromuscular transmission: Binds acetylcholine released from motor [neurons](/entities/neurons) to trigger muscle contraction
Fast synaptic signaling: Mediates excitatory neurotransmission at the motor endplate
Muscle fiber type specification: Influences development and maintenance of neuromuscular junctions
CHRNA1 receptors are also expressed in some neuronal populations in the CNS, where they contribute to cholinergic signaling.
neurodegeneration" style="color:#4fc3f7;margin:1.5rem 0 0.6rem;font-size:1.15rem;font-weight:700;border-bottom:2px solid rgba(79,195,247,0.3);padding-bottom:0.3rem">Role in Neurodegeneration
While CHRNA1 is primarily associated with neuromuscular junction function, it has relevance to neurodegenerative processes:
Alzheimer's Disease
Cholinergic neurons degenerate in AD, leading to loss of nAChR signaling
Alpha-1 subunit expression may be affected in spinal motor neurons in AD
Relationship to neuromuscular dysfunction observed in some AD patients
May contribute to neuromuscular weakness in neurodegenerative diseases
Therapeutic Targeting
Drug Development
Nicotinic agonists: Compounds targeting alpha-1 containing receptors for neuromuscular disorders
Positive allosteric modulators: Enhance receptor function in hypofunctional states
Research Applications
Gene therapy approaches for congenital myasthenic syndromes
Stem cell-derived motor neurons for disease modeling
Key Publications
[@sine2012]: Sine SM. [End-plate acetylcholine receptor: structure, mechanism, pharmacology, and disease](https://pubmed.ncbi.nlm.nih.gov/22688476/). Physiol Rev. 2012;92(3):1189-1234.